• Phase

    Startup

  • Contact person

    Helene Hartman, CEO

  • Email

    helene.hartman@xinnate.com

  • Area

    Pharma & Biotech

Xinnate

Xinnate AB develops proprietary peptides for prevention and treatment of wound and topical applications. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations.

Did you know?

The body’s natural defence to promote healing is the secret in Xinnate´s gel.

© 2020 Copyright SmiLe Incubator